EGFR and breast carcinoma: The enzyme activity assay of the most active compound 31 toward the MDA-MB-231 breast cancer cell line was selected as representative example of the compounds and administered at a single concentration (10 μM) against EGFR-TK to investigate the mechanism of action of the newly synthesized compounds33.